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SUMMARY 
We tested the hypothesis that treatment of growing, suscep-
tible dogs with glycosaminoglycan polysulfates would mitigate the 
signs of incipient hip dysplasia. In one experiment, seven pups, 
randomly selected from two litters, were injected intramuscularly 
twice weekly with 2.5 mg per Kg body weight glycosaminoglycan 
polysulfates (Adequan°) and seven control pups received sterile 
buffered 0.9% saline from six weeks to eight months of age. The 
' hip joints of the dogs were examined by radiography with dogs in 
the standard, legs-extended position. At eight months of age all 
dogs in this experiment had no femoral head subluxation on 
radiographic examination. The Norberg angles, a measure of 
coxofemoral congruity, improved from a mean of 102 ± 1 degrees in 
controls to 106 ± 1 degrees in the drug treated group (p = 0.008). 
These dogs were not subjected to necropsy. 
In a second experiment, eight pups were randomly selected 
from two litters and were injected intramuscularly twice weekly 
with 5.0 mg per Kg glycosaminoglycan polysulfates (Adequan°) from 
six weeks to eight months of age. Similarly, eight control pups 
were injected with saline. At eight months of age hip joints 
were examined by radiography with dogs in the standard position, 
and at necropsy intra-articular tissues were evaluated macro-
scopically and biochemically. Eight of eight dogs in the drug 
treated group had no subluxation on radiographic examination, 
whereas four of eight control dogs had femoral head subluxation. 
The mean Norberg angles on the radiographs were 109.7 ± 1.6 
degrees for the treated group and 101.5 ± 1.6 degrees for con-
trols, representing a mean improvement in coxofemoral congruity 
of 8.2 degrees in the drug treated dogs. The radiographic 
diagnoses (normal vs. dysplastic) and the Norberg angle 
measurements were significantly different (p = 0.04 and 0.002, 
respectively) for the treated and control groups. 
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At necropsy one of eight dogs in the drug treated group had 
cartilage degeneration, whereas four of eight dogs in the control 
group had cartilage degeneration. The mean pathologic score 
determined for the hip joints of dogs in the treated group was 
1.6 ± 0.8 whereas for controls the score was 3.3 ± 1.2 (p = 
0.09). Normal (disease-free) dogs had hip pathologic scores of 
zero. The mean fibronectin content of femoral head articular 
cartilage was reduced from 2.19 ± 0.61 ~g/mg in untreated dogs to 
0.59 ± 0.56 ~g/mg for drug treated dogs (p = 0.04). Fibronectin 
content was used as a measure of the extent of cartilage degen-
eration, and the cartilage of disease-free hip joints contained 
0.32 ± 0.03 ~g per mg. The mean proteoglycan content of the 
cartilage was unaffected by the drug treatment. There was a 
trend for lower synovial fluid volume and lower ligament volume 
(more normal volumes) in the treated dogs, but the differences 
were not statistically significant. 
Hip joint laxity was assessed with a distraction method 
during radiographic examinations of the dogs in both Experiments 
1 and 2. The differences in laxity determinations between the 
drug treated and control groups were not statistically significant. 
Taken together, the data suggested that intramuscular treat-
ment with glycosaminoglycan polysulfates from six weeks to eight 
months ·of age of growing pups which were susceptible to hip 
dysplasia resulted in less subluxation as determined from the 
i 
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standard radiographic projection. The dogs in the treated groups 
had closer coxofemoral congruity when they were eight months ·old; 
at necropsy the joint pathologic scores of treated dogs had a 
trend to improvement, but the differences were not statistically 
significant. The mechanism of action for this drug effect is 
unknown. 
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FOOTNOTES 
a. Agway Big Red High Energy, Pro-Vet, Newark, Delaware. 
b. P/D Canine, Hill's Pet Products, Topeka, Kansas. 
c. Corid, MSD- Agvet Merck Co., Rahway, New Jersey. 
d. Norden Laboratories, Lincoln, Nebraska. 
e. Purchased from a distributer; Butler Company, Rochester, New 
York, who obtained the drug, Adequan®, from Luitpold 
Pharmaceuticals, Inc., Shirley, New York. 
f. Procedure of General Diagnostics, Organon Teknika Corp., 
Durham, North Carolina. 
g. Picker (G5255), 500 milliampere, 90 kilovolt radiography 
unit, Rochester, New York. 
h. Prom-Ace (10 mg/ml), Aveco, Fort Dodge, Iowa. 
i. Biotol (5% solution in distilled water), Boehringer 
Ingelheim, St. Joseph, Missouri. 
j. Dr. Gail K. Smith, personal communication 
k. Beuthanasia, Schering Co., Kenilworth, New Jersey 
1. Luitpold Pharmaceuticals, Inc., Shirley, New York. 
m. R.J. Todhunter and G. Lust, unpublished data. 
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INTRODUCTION 
Hip dysplasia continues to be of concern for dog owners·and 
veterinarians because joint pain, restricted motion, osteo-
arthritis, and lameness are associated with the condition. It is 
widely accepted that hip dysplasia has a hereditary basis, but 
the cause of the hip abnormality is not known (for a review see 
Ref. #1). Some years ago preliminary evidence from several 
investigators suggested the usefulness of limiting food intake in 
growing dogs in order to delay the onset, lessen the severity'of 
pathological signs, and even prevent hip dysplasia in some 
dogs 2 • 3 • 4 • This concept recently received strong support in a 
st.udy which substantiated that limited food and the resulting 
slower weight gain during the growth period resulted in better 
hip conformation and less hip dysplasia5 • 
Short of surgical interventions and also antiarthritic-
analgesic, non-steroidal or steroidal therapy to increase joint 
function, there is no medical treatment available to ameliorate 
or reverse the progression of the disease. Several recent 
reports claimed that intra-articular or intramuscular injections 
of glycosaminoglycan polysulfates lessened the pathological 
changes of surgically induced osteoarthritis in stifle joints of 
rabbits and dogs 6• 7• 8• 9 • Since dogs with hip dysplasia invariably 
have evidence of osteoarthritis in the hip joints, it was of 
interest to examine if prophylactic treatment of susceptible, 
growing dogs with glycosaminoglycan polysulfates would diminish 
the occurrence of the hip joint tissue abnormalities that precede 
or are a part of bip dysplasia. The studies described here were 
designed to test the hypothesis that treatment of susceptible 
• 
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pups during most of their growth period with glycosaminoglycan 
polysulfates would mitigate the signs of incipient hip dysplasia. 
MATERIALS AND METHODS 
Dogs. Labrador retrievers bred and raised at this laboratory 
were used. Four litters of pups were studied. Experiment 1: 
Litter "a" was six pups from a normal male with good hip joint 
conformation mated to a normal female with fair hip conformation. 
Litter "d" was eight pups from a male with dysplastic parents,' 
but with good hip conformation at 12 months of age at the time of 
mating to a female with bilateral severe hip dysplasia with 
evidence of degenerative joint disease. Experiment 2: Litter 
"f" was eight pups from a male with severe hip dysplasia with 
degenerative joint disease mated to a female with moderate hip 
dysplasia with degenerative joint disease. Litter "g" was eight 
pups from a male with severe hip dysplasia mated to a female with 
severe hip dysplasia with degenerative joint disease. 
Nursing pups were supplemented with evaporated milk and 
cereal at three weeks of age. Dog food, drya and canned meat,b 
were gradually added until weaning at five-six weeks. Dry dog 
fooda supplemented with canned meatb was fed to six months; 
followed by dry fooda only to eight months of age. All dogs were 
allowed dry food and water ad libitum. Pups were treated for 
coccidiac at three and six weeks of age; wormed at eight and 
eleven weeks, and at 24 and 27 weeks. First standard vaccina-
tionsd were at four and six weeks with measles, distemper and 
parvovirus vaccine as prescribed by the manufacturer. At 8, 12 
16, and 24 weeks the dogs were vaccinated with five-way vaccine 
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(DA2 PL-CPV) . Individual dogs were weighed at weekly intervals 
and the body weights were recorded. 
Drug Administration. A preparation of glycosaminoglycan poly-
sulfates (molecular weights 4-16 kD) was purchased from a 
commercial company.e Experiment 1: An equal number of pups from 
each litter (4 from "a" and 3 from "d") were assigned at random 
to receive the drug treatment or the control treatment. Drug 
treated pups were injected intramuscularly with 2.5 mg glycos~ 
aminoglycan polysulfates per Kg body weight twice weekly (Monday 
and Thursday) alternating left and right hind legs starting at 
six weeks and ending at eight months of age. Untreated controls 
were injected intramuscularly with a matched volume of sterile 
phosphate buffered (pH 7.2) 0.9% saline, on the same schedule. 
Experiment 2: Four pups from each litter ("f" and "g") were 
selected at random to receive the drug treatment or the control 
treatment. Treated pups were injected intramuscularly with 5.0 
mg/Kg glycosaminoglycan polysulfates twice weekly from six weeks 
to eight months of age. Untreated controls were injected with a 
matched volume of buffered saline in the same way as the controls 
for Experiment 1. 
Activated partial thromboplastin timet was assessed on plasma of 
six dogs from litter "a" of Experiment 1 and from eight dogs of 
litter "f" in Experiment 2. The blood was collected and the 
analyses were done when dogs in each litter were six months old. 
This test utilized the reported mild heparin-like activity9 of 
glycosaminoglycan polysulfates to ascertain if the drug reached 
the blood. 
Radiographic Examination 
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Dogs were examinedg under anesthesia at four, six and eight 
months of age for hip joint conformation with respect to hip 
dysplasia. The standard legs extended, dorsal recumbency, ventro 
dorsal radiographic examination was done. 10 • 11 Dogs initially were 
calmed with injection of 0.5 ml tranquilizer,h followed by 
anesthesia,i using up to 8 ml of a 5% solutioni administered 
slowly until the toe-pinch, withdrawal reflex was negative. 
Anesthetized dogs also were examined for the extent of hip joint 
distraction, an estimate of laxity, as described by Smith et 
al. 12 • For this procedure the anesthetized dogs were positioned 
on their backs in a standard plastic cradle and a foam-rubber 
cushion, and were tied down to the x-ray table with velcro 
straps. An examiner (GL) stood behind a lead-shielded, mobile 
board with a lead-lined window and two openings for the radio-
graphic safety gloves to pass through. The examiner squeezed the 
stifles medially (femurs nearly perpendicular to the table top) 
while a device ]Ylade by Smith et al. 12 'j was positioned between the 
thighs. The distraction device also was held in place by the 
velcro straps. 
Evaluation of Radiographs 
The standard legs-extended radiographs initially were 
evaluated as normal or dysplastic (GL, KAB), and graded further 
(KAB) as excellent, good or fair normal joints, or mild, moderate 
,t 
or severe hip dysplasia as described in a booklet by the 
Orthopaedic Foundation for Animals. 13 A radiographic score was 
used by assigning corresponding numbers of 1, 2, 3, 4, 5, 6 to 
the diagnoses from excellent to severe. On the radiographs a 
Norberg angle measurement was made5 • 10' 11 and a center-edge angle 
measurement was made. 14 Data were recorded as degrees. 
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The method of Smith et al. 12 was used to determine the joint 
distraction distance (mm) between the geometric center of the 
femoral heads and acetabulae and a distraction index was calc~­
lated by dividing the distance by the radius of the femoral 
head. 12 This represented an estimate of joint laxity. The 
method of Belkoff et al. 15 also was used on the radiographs of 
the distracted joints to assess the percent of coverage of 
femoral heads by the cranial side of acetabulae. This measure-
ment also was associated with joint laxity15 and served as 
another estimate of laxity after joint distraction. The original 
procedure of Belkoff et al. positioned femurs at a 45° angle for 
distraction, whereas for the method of Smith et al. the femurs 
are in a neutral (more perpendicular) position. 
Necropsy Examination 
Not all dogs in Experiment 1 were examined at necropsy at 
eight months of age; the joints of some dogs in this group were 
examined subsequently, but observations were not available for 
all dogs at eight months of age and data were not included here. 
All dogs in Experiment 2 were killed with an overdose of 
barbituratek at eight months of age immediately after radio-
graphic examinations. Hip joints and shoulder joints were 
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dissected out and placed in crushed ice. Within two hours after 
death, joints were examined for cartilage degeneration, macro-
scopic presence of synovitis, synovial fluid and round ligament 
·volume. 10• 11 • 16• 17 Samples of articular cartilage from the known 
site of lesion predilection on femoral heads16• 17 were collected 
and stored frozen (-20°C) . Cartilage from the weight bearing 
region of the humeral head also was collected and frozen. 
Fibronectin and proteoglycan contents of the articular cartilage 
samples were determined as described by Burton-Wurster and 
Lust. 18 • 19 Experiments were done to establish that glycos-
aminoglycan polysulfates did not interfere in the ELISA test for 
fibronectin. This was determined by adding known quantities of 
glycosaminoglycan polysulfates to the extraction solutions of 
fibronectins and then using the ELISA. 
A pathologic score was devised by assigning numbers to joint 
tissue abnormalities as follows: macroscopic appearance of 
normal synovium = 0, normal articular cartilage = 0, synovial 
fluid volume less than 0.3 ml = 0, ligament volume less than 0.7 
ml = 0. Synovitis = 1, cartilage degeneration= 1, synovial 
fluid volume 0.3 - 0.8 ml = 1, greater than 0.8 ml = 2; ligament 
volume 0.7- 1.1 ml = 1, ligament volume greater than 1.1 ml = 2; 
proteoglycan content of cartilage greater than 30 ~g/mg = 0, 20 -
29 ~g/mg = 1, 5 - 19 ~g/mg = 2; fibronectin content of cartilage 
less than 0.4 ~g/mg = 0, 0.4 - 1.0 ~g/ml = 1, greater than 1.0 
~g/mg =2. The additive joint pathologic score was averaged per 
dog. Normal, disease free, dogs had scores of 0. 
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Experimental Design and Statistical Analysis 
Two experiments were done, testing the effect of two doses 
of glycosaminoglycan polysulfates on the manifestation of signs 
of hip dysplasia in Labrador retriever dogs. Experiment 1 used 
2.5 mg/kg drug and Experiment 2 used 5.0 mg/kg drug. Evidence 
was sought for the efficacy of the drug in reducing the frequency 
or mitigating the signs of hip dysplasia. Both Experiments 1 and 
2 had a randomized complete block design with the block being the 
litter. Two litters were used in each experiment. Different 
dams and sires were mated to produce four litters; litters were 
independent. An equal number of pups from each litter were 
assigned at random to receive either drug treatment or control 
treatment (saline solution) . There was replication of treatments 
within each block (randomized complete block design with replica-
tion in each block). This allowed for a check of difference in 
response to the treatments between litters rather than assuming 
that no variation existed. 
The Cochran-Mantel-Haenszel test20 was used to assess the 
difference between the treated and control groups in the 
proportion of dogs having hip dysplasia, after controlling for 
litter effects. Quantitative data were analyzed as a randomized 
block design, where litter was the blocking factor, to test for 
effects of drug. Since the "a priori" research hypothesis was 
that the drug treatment should reduce the signs of hip dysplasia, 
one-sided tests of treatment effects were appropriate. Partial 
correlations among the quantitative measures of hip dysplasia 
also were calculated to check the conformity of the different 
measures, after controlling for variation in the data due to 
litter and treatment effects. 
RESULTS 
General Observations 
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The growing dogs used in these studies tolerated the drug 
and placebo treatment without apparent untoward effects. The 
repeated injections were not painful. Pups grew at a conven-
tional rate, and at necropsy (Experiment 2) no obvious abnor-
malities were noted at the sites of injections in the hind limbs. 
Activated Partial Thromboplastin Time 
An activated partial thromboplastin time (APTT) was 
determined using one litter (a) of Experiment 1 and one litter 
(f) of Experiment 2 when pups were six months old to assess 
whether the injected glycosaminoglycan polysulfate actually was 
utilized by the treated dogs. The data were obtained (measured 
in seconds) at 0, 1, 2, 3, 4, 6, 27 hours after intramuscular 
injection of the drug. Data are listed in Table 1. Dogs in 
litters (d) and (g) were not studied for APTT. 
There was no difference in APTT at hour 0 for the two groups 
of Experiment 1 (p = 0.6779) or of Experiment 2 (p = 0.7663). 
The mean initial APTT were 14.83 ± 0.26 and 14.67 ± 0.26 seconds, 
respectively, for the treated and control groups of Experiment 1 
and 14.50 ± 0.57 and 14.75 ± 0.57 seconds, respectively, for 
Experiment 2. For each dog in the control group, APTT did not 
change with time from the time of drug administration, measured 
as hours or as the natural logarithm of hours (i.e., the slope 
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was zero). However, for each drug treated dog, the APTT (after 
time 0) decreased linearly with the natural logarithm of time. 
The rate of change in APTT differed significantly between the two 
groups (Experiment 1: p = 0.005 and Experiment 2: p = 0.0016), 
with the slope for the treated group being smaller than that of 
the control group, as expected. The mean APTT after drug was 
significantly greater for the drug group than the control group 
(Experiment 1: p = 0.0011 and Experiment 2: p = 0.0000). The 
mean APTT after the start of the assay were 19.33 ± 0.46 and 
14.80 ± 0.46 seconds, respectively, for the treated and control 
groups of Experiment 1 and 19.33 ± 0.29 and 14.00 ± 0.29 seconds, 
respectively, for Experiment 2. 
Because data for some assay times were missing for some of 
the dogs in each group of Experiment 1, an analysis, which com-
pared the two groups for APTT at four to six hours after drug, 
was performed. The mean APTT at four to six hours was signifi-
cantly higher for the drug group than the control group (p = 
0.0031). The mean APTT at four to six hours were 19.00 ± 0.51 
and 15.17 ± 0.51 seconds, respectively, for the drug and control 
groups. 
The mean APTT at one to two hours after drug was compared 
for the two experiments. There was evidence of an interaction 
between experiment and treatment (p = 0.0800), indicating that 
the magnitude of the difference in APTT at one to two hours for 
drug and control groups differed for the two experiments. For 
each experiment, the mean APTT at one to two hours after drug 
injection was significantly greater for the treated than the 
control group: Experiment 1: p = 0.00005; drug treated: 21.33 ± 
0.33 seconds, and controls: 14.67 ± 0.33 seconds; Experiment 2: 
p = 0.0001; drug treated: 23.75 ± 0.88 seconds, and controls: 
14.13 ± 0.88 seconds. 
Growth of Pups 
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The weight (kg) of each pup was taken each week for the 
duration of each experiment. In Experiment 1, weights were 
measured starting at six weeks (1.5 months) and continued to be 
taken through 38 weeks (9.5 months). In Experiment 2, weights 
were measured during weeks six through 35 (1.5 through 8.75 
months) for litter (f) and during weeks seven through 35 (1.75 
through 8.75 months) for litter (g). Individual growth curves 
were fit to the data for each dog. Growth exhibited a curvi-
linear pattern in which weight increased with age but the rate of 
weight gain tapered off toward the end of the experiment. No lag 
in weight gain was found for any dog during the first weeks of 
the experiments nor was there a strong leveling off of weight for 
any dog by the termination of the experiment, although the growth 
rate did decline during the last few weeks of each experiment. 
Figure 1 shows the average growth curves for the treated and 
control groups of litters (a) and (d), respectively, of Experi-
ment 1. Figure 1 also gives the corresponding plots for litters 
(f) and (g) of Experiment 2. For visual clarity, the 95% confi-
dence bands for the average curves were omitted. 
The individual growth curve for each dog was summarized by 
three statistics: the mean weight for the duration of the 
experiment (mean), the rate of weight gain for the experiment 
(slope= linear component), and the tapering of the growth rate 
• 
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(curvature = quadratic component) . The values of the summary 
statistics of growth for each dog were used as the data in the 
randomized complete block model to test for an effect of drug 
treatment on the growth of dogs. 
Table 2 gives the summary measures of growth for the two 
experiments. There was no statistically significant effect of 
drug treatment on mean weight, growth rate or tapering off of 
growth rate for either experiment: Experiment 1: p = 0.4068, 
0.2702 and 0.2317, respectively; Experiment 2: p = 0.1057, 0.7612 
and 0.8594, respectively. In addition, an analysis using the 
data from the two experiments was performed to test whether the 
effect of drug on growth differed between the two experiments. 
There was no significant interaction between experiment and 
treatment for any of the three summary measures of growth 
(p = 0.3451, 0.1048 and 0.1019, for mean, slope and curvature, 
respectively), indicating that the difference in response between 
the drug and control groups was similar for the two experiments. 
There was no main effect of drug treatment on any of the summary 
measures of growth as well (p = 0.8437, 0.4719 and 0.4561 for 
mean, slope and curvature, respectively)~ indicating that there 
was not a significant difference in growth between the treatment 
and control groups. Finally, there was no statistically signifi-
cant difference between the two experiments in mean weight, rate 
of weight gain or tapering of growth rate (p = 0.5809, 0.4887 and 
0.4965, respectively). It was concluded that the growth of pups 
was similar in the two experiments and no statistically signifi-
cant differences in growth due to drug treatment were found. 
.t 
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Changes in Norberg Angle with Time 
The Norberg angle of each pup was measured at four and eight 
months of age in Experiment 1 and at four, six and eight months 
of age in Experiment 2. In general, the Norberg angle increased 
over the period from four to eight months of age for the pups in 
each experiment. 
For Experiment 2, one could assess whether a linear trend in 
Norberg angle with age existed for each pup. The mean Norberg 
angle over the period from four to eight months of age and the 
rate of change in Norberg angle over that period (the slope) were 
used as summary statistics in comparing time trends in Norberg 
angle between the treated and control groups. 
Table 3 gives the mean Norberg angles at each age for the 
treated and control groups of each experiment as well as the mean 
difference in Norberg angle from ages four to eight months for 
the two treatment groups of each experiment. At four months of 
age, there was no significant difference in Norberg angle between 
the two groups for either experiment (Experiment 1: p = 0.0873; 
Experiment 2: p = 0.2396), although the mean Norberg angle of the 
drug group was greater than that of the aontrol group. At eight 
months of age, the Norberg angle was significantly greater for 
the drug group than the control group for both experiments 
(Experiment 1: p = 0.0081; Experiment 2: p = 0.0016). For 
Experiment 2, the Norberg angle at six months was significantly 
greater for the treated group than the control group (p = 0.0065). 
The difference in Norberg angle from ages four to eight months 
was significantly greater for the treated group than the control 
group for Experiment 2 (p = 0.0004); whereas, for Experiment 1, 
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there was no statistically significant difference between groups 
in mean difference in angle (p = 0.3489). 
In addition, an analysis using the data from the two experi-
ments was performed to test whether the two experiments differed 
in the effect of drug on Norberg angle at four months, Norberg 
angle at eight months, or the difference in angle over the period 
of four to eight months of age. There was no significant 
interaction between experiment and treatment for Norberg angle at 
four months or Norberg angle at eight months (p = 0.5701 and 
0.1600, respectively), suggesting that the difference in response 
between the drug and control groups was similar for the two 
experiments. However, there was a significant interaction of 
treatment and experiment for difference in Norberg angle (p = 
0.0226). Hence, the separate analyses must be used for the 
difference in angle. There was no main effect of drug treatment 
on Norberg angle at four months (p = 0.0782), indicating that the 
Norberg angle at four months was not significantly greater for 
the drug group than the control group; however, the Norberg angle 
at 8 months was significantly greater for the drug group than the 
control group (p = 0.0001). Finally, there was no statistically 
significant difference between the two experiments for Norberg 
angle at either four months or eight months of age (p = 0.4057; 
p = 0.5901, respectively). 
The improvement in coxofemoral congruity was expressed as 
the change in degrees (~0 ) due to drug treatment and was 
calculated for each age of each litter as the mean angle of the 
treated group minus mean angle of the control. Table 3 gives the 
mean ~o for each age of each experiment. Analysis of the 
improvement data suggested that there was no difference between 
experiments for improvement at four months of age or at eight 
months of age (p = 0.8520 and 0.1358, respectively). 
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In summary, the effect of the drug on Norberg angle at four 
or at eight months of age was similar for the two experiments. 
There was no statistically significant treatment effect on 
Norberg angle at four months of age, but the Norberg angle at 
eight months of age was significantly greater for the drug 
treated dogs than the control dogs. The change in Norberg angle 
over the period of four to eight months of age differed for the 
two experiments: the difference in Norberg angle was signifi-
cantly greater for the treated group than the control group for 
Experiment 2; whereas there was no statistically significant 
difference between treatment groups for Experiment 1. 
Summary of Experiment 1 
Experiments 1 and 2 both ended when dogs reached eight 
months of age. The data obtained at this time period are 
presented in Tables 4-8; Table 4 lists data for dogs in 
Experiment 1 and Tables 5-8 pertain to Experiment 2. 
Data on the effects of biweekly injections of 2.5 mg/kg 
glycosaminoglycan polysulfate on hip joint radiographic para-
meters at eight months of age are listed in Table 4. Only the 
Norberg angle and the center-edge measurements were significantly 
different between controls and drug treated dogs. The center-
edge angles, although determined independently, estimated joint 
congruity as did Norberg angles. Thus the center-edge angle 
determinations substantiated the Norberg angle determinations. 
i 
19 
Summary of Experiment 2 
In addition to radiographic examination, hip joints of the 
dogs in Experiment 2 also were observed at necropsy at eight 
months of age. Data for individual pups for Norberg angles, 
radiographic score, and pathologic score are presented in Table 
5. The population mean values for the observed radiographic and 
intra-articular parameters are listed in Table 6. It can be 
noted that the radiographic diagnoses, Norberg angles, and 
center-edge angles were significantly different between controls 
and treated dogs. The mean pathologic scores were 3.3 ± 0.9 and 
1.6 ± 0.9 for controls and treated respectively, but the 
difference was not statistically significant (p = .09). 
Biochemical analysis of articular cartilage disclosed that the 
mean fibronectin content was significantly different between 
controls and treated dogs. The fibronectin content of articular 
cartilage from disease-free joints was 0.32 ± 0.03 ~g/mg wet 
cartilage (also see Tables 7 and 8) . 
In Table 7 values for the experimental observations (i.e., 
data from Table 6) are compared with values calculated for the 
disease-free joints and for the dysplastic joints respectively 
from Experiment 2. These values can be compared to previously 
published numbers from the literature, called "expected" values 
in Table 7. 
Data are presented suggesting that glycosaminoglycan 
polysulfates treatment had no effect on the fibronectin and 
proteoglycan content of humeral head articular cartilage and on 
synovial fluid volume in disease-free shoulder joints from the 
dogs in Experiment 2 (Table 8). 
i 
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Correlation of Measures 
Partial correlations among quantitative measures of hip 
joint conformation were calculated to check for the conformity of 
the different measures, after controlling for the variation in 
the data due to litter and treatment effects. In Experiment 1 
center-edge angle was negatively correlated with radiographic 
score (r = -0.62, p = 0.054) and as expected highly positively 
correlated with Norberg angle (r = 0.90, p = 0.0004). Femoral 
head coverage percent was negatively correlated with distraction 
length (r = -0.94, p = 0.0001) and index (r = -0.95, p = 0.0001). 
Distraction length was positively correlated with distraction 
index (r = 0.99, p = 0.0001). 
For Experiment 2, radiographic score was correlated 
positively with synovial fluid volume (r = 0.95, p = 0.0001), 
and negatively with Norberg angle (r = -0.82, p = 0.0006) and 
center-edge angle (r = -0.86, p = 0.0002). Norberg angle was 
highly positively correlated with center-edge angle (r = 0.97, 
p = 0.0001) and with femoral head coverage percent (r = 0.95, 
p = 0.0001) and negatively with distraction length and index 
(r = -0.90, p = 0.0001) with synovial fl~id volume (r = -0.84, 
p = 0.0003) and with pathologic score (r = -0.85, p = 0.0002). 
Distraction index was negatively correlated with femoral head 
coverage percent (r = -0.90; p = 0.0001). Pathologic score was 
positively correlated with fibronectin content (r = 0.85, p = 
0.0002) and with synovial fluid volume (r = 0.84, p = 0.0003). 
Ligament volume exhibited no strong relationship with any of the 
other measures. 
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DISCUSSION 
The data presented suggested that early treatment of 
susceptible pups with glycosaminoglycan polysulfates reduced the 
signs of incipient hip dysplasia. The drug treatment was 
continued from six weeks to eight months of age and it is not 
possible to predict if the beneficial effects observed at eight 
months of age would persist in the future. Additional studies 
are needed to answer that question. 
The goal of this study was to ascertain a drug effect on 
early signs of hip dysplasia during the developmental phase of 
the disease, which coincides in general terms with the growth 
period of dogs. The initial radiographic evidence for hip 
dysplasia can be observed between three and twelve months of age 
in Labrador retrievers. 17 Six months was reported to be the most 
frequent age for the initial appearance of hip dysplasia and 
about 50% of susceptible pups had signs of abnormality on 
radiographs at this time; at eight months 60-70% were dysplastic. 
At six and eight months some dogs that appeared to be disease-
free on radiographic examination had hip joint abnormalities. 17 
It is not known to what extent the severity of disease in parents 
influences the time of disease onset in their progeny. It was 
reasoned that from weaning to eight months was an appropriate 
period to evaluate a prophylactic therapy with a promising drug. 
The drug, glycosaminoglycan polysulfates (molecular weights 
4-16 kD), is a product isolated from bovine tracheal cartilage 
and is polysulfated synthetically. 7 ' 8 ' 9 Previously several reports 
appeared with data suggesting that this drug had been effective 
in reducing cartilage degeneration and in inhibiting proteases 
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and in promoting proteoglycan formation in stifle joints of dogs 
and also rabbits when cruciate ligaments had been resected at 
surgery in order to create an unstable stifle joint and 
subsequently osteoarthritis. 6' 7 ' 8 Similar results also have been 
claimed by authors for the treatment of osteoarthritis in 
horses21 and in humans. 9 
The data of the present study suggested that drug treatment 
resulted in improved coxo-femoral congruity as assessed by 
Norberg angle5 ' 10 ' 11 and center-edge measurements. 14 These two 
measurements were made independently on radiographs in this study 
and provide an effective means to quantify the position of the 
center of the femoral head in relation to its acetabulum in the 
hip joint. Corresponding intra-articular effects of the drug 
were a trend for lower synovial fluid and round ligament volume 
and a significant reduction of cartilage fibronectin content. 
The proteoglycan content of the lesion area of femoral heads was 
not different in treated and control dogs. The observed joint 
pathologic score had a trend toward normal in the treated dogs, 
but the means were not statistically different between controls 
and treated dogs. The observations on the hip joint tissues help 
support the conclusion from the radiographic evaluation that drug 
treatment on average was associated with a better hip joint. 
Of interest for the pathogenesis of hip dysplasia was that 
a measure of hip joint capsular laxity, i.e., femoral head 
distraction, 12 ' 15 apparently was unaffected by the treatment. The 
mean values for femoral head coverage percent, distraction length 
and distraction index were not significantly different although 
in Experiment 2 the mean values appeared to be reduced in the 
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treated dogs (see Table 4 and 6). Smith et a1. 12 proposed that a 
distraction index of 0.3 or less is associated with less degen-
erative joint disease. If our observations were substantiated 
after further study, it suggests the possibility that the mean 
laxity identified in the dogs of this study was inherently 
abnormal and that the drug only delayed the onset or reduced the 
signs of disease in the treatment groups. It would require 
follow-up studies to subtantiate this. An alternative 
explanation for the data might be that a certain amount of laxity 
is a phenomenon associated with hip joints, but is not critical 
or causal for disease progression to hip dysplasia. 
The data do not readily suggest a mechanism of action for 
glycosaminoglycan polysulfates in this study. Possibilities 
include an as yet unknown effect on muscle tissues and/or on the 
development of bone, as well as the previously postulated6• 7 • 8 
protective effects on cartilage and inhibitory effects on 
cartilage proteinases. The possibility that bone metabolism 
might be involved was suggested by data from a recent studym 
wherein intra-articular administration of glycosaminoglycan 
polysulfate caused a striking increase in technetium-99-methylene 
diphosphonate uptake into subchondral bone of equine carpus 
joints. m,zz Other investigators recently reported that signs of 
hip dysplasia in dogs also were reduced and/or abated at six 
months of age when Labrador retriever pups were fed 25% less food 
than a control group. In that report5 it was observed that the 
improvement of hip joint congruity persisted in the test dogs 
until two years of age. Those authors did not propose a mechan-
ism of action for the limited food effect. Thus, there are now 
I 
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two methods, i.e., glycosaminoglycan polysulfates therapy and 
limited food consumption, that promote the reduction of the signs 
of incipient hip dysplasia in dogs. It is reasonable to propose 
that future studies aimed at elucidating the mechanism of action 
of these two phenomena will help us in understanding the cause of 
hip dysplasia in dogs. 
I 
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Table 1. Effects of one intramuscular injection of 
glycosaminoglycan polysulfates on plasma activated partial 
thromboplastin time. 
Hours ExQeriment 1 ExQeriment 2 
post Untreated Drug Untreated Drug 
28 
Injection Controls Treated Controls Treated 
. . . . . . . . . . seconds. . . . . . 
0 14.5 ± 0.6 14.8 ± 0.5 14.8 ± 0.5 14.5 ± 0.6 
1 15.0 ± 0.0 20.5 ± 0.7 13.5 ± 0.5 23.0 ± 2.1 
2 14.8 ± 0.5 21.7 ± 0.5 14.7 ± 0.3 24.5 ± 0.5 
3 N/A* N/A 14.0 ± 0.4 20.8 ± 0.5 
4 15.5 ± 0.7 19.5 ± 0.7 13.8 ± 0.3 17.0 ± 0.0 
6 14.5 ± 0.7 19.0 ± 1.4 13.5 ± 0.3 16.0 ± 0.7 
27 14.5 ± 0.7 15.0 ± 0.0 14.5 ± 0.3 14.7 ± 0.5 
For Experiment 1: controls and treated groups n = 3 each. 
For Experiment 2: controls and treated groups n = 4 each. 
Data as means and standard error. 
*N/A: Data not available. 
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Table 2. Means of the summary data of growth for the two drug 
experiments. 
Ex2eriment 1 Ex2eriment 2 
Untreated Drug Untreated Drug 
Controls Treated Controls Treated 
Mean 15.27 16.16 17.43 16.88 
Weight (0.76) (0.76) (0.76) (0.71) 
(kg) 
Growth 5.28 5.98 6.98 6.71 
Rate (0.29) (0.29) (0. 29) (0.27) 
(kg/month) 
Decline -0.22 -0.27 -0.34 -0.32 
in Growth (0.02) (0.02) (0.02) (0.02) 
Rate 
(kg/month2 ) 
Individual growth curves were fit to the data for each dog and 
each curve was summarized by three statistics: mean weight (the 
pivot point of the curve), growth rate (the linear component of 
the curve) and decline in growth rate (the curvature) . The mean 
weight is the average weight of a pup over the period from 1.5 to 
8.0 months. The growth rate is the rate-of weight gain of a pup 
over the experimental period, as measured by the slope of the 
data. The decline in growth rate is the tapering off of increase 
in weight for a pup, as measured by the curvature in weight as a 
function of age. The standard errors of the summary statistics 
are given in parentheses. The drug doses were 2.5 and 5.0 mg/kg 
body weight for Experiments 1 and 2, respectively. 
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.Table 3. Changes in Norberg angle with time for two experiments. 
ExQeriment 1 ExQeriment 2 
Untreated Drug Untreated Drug 
Controls Treated flo Controls Treated flo 
Norberg angle 96.7 99.76 2.3 99.4 100.8 1.3 
at 4 months (o) (1. 5) (1. 5) (3. 3) (1. 4) (1. 4) (3. 3) 
Norberg angle N/A* N/A 103.1 109.7 6.5 
at 6 months ( 0) ( 1. 6) (1. 6) (2. 4) 
Norberg angle 102.2 106.3 4.0 101.5 109.7 8.2 
at 8 months ( 0) (1. 0) (1. 0) (1. 2) (1. 6) (1. 6) (1. 2) 
Difference 5.5 6.3 2.1 8.9 
in angle (1. 4) (1. 3) (1.1) (1.1) 
*NA: Data not available. 
Mean Norberg angle at four, six, and eight months of age and mean 
difference in angle from four to eight months of age for the two 
drug experiments. The difference in Norberg angle over the 
period of four to eight months of age was calculated for each dog 
as angle at eight months minus angle at four months. The 
improvement in coxofemoral congruity was expressed as the change 
in degrees (flo), calculated as mean of treated minus mean of 
control for each litter. The standard errors are given in 
parentheses. The drug doses were 2.5 and 5.0 mg/kg body weight 
for Experiments 1 and 2, respectively. 
' •• 
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Table 4. Effects of intramuscular injections of 2.5 mg/Kg 
glycosaminoglycan polysulfates on hip joint radiographic 
parameters at eight months of age. 
Untreated Drug Probability 
Controls Treated p 
Diagnosis 7 N; 0 D 6 N*; 0 D 0.39 
Radiographic Score 2.2 ± 0.4 2.0 ± 0.4 0.52 
Norberg Angle (degrees) 102.2 ± 1.0 106.3 ± 1.0 0.008 
Center-edge Angle (degrees) 13.0 ± 0.8 17.7 ± 0.9 0.002 
Femoral head coverage (%) 35.6 ± 3.1 40.9 ± 3.4 0.27 
Distraction (mm) 6.4 ± 0.75 6.1 ± 0.07 0.80 
Distraction index 0.55 ± 0.06 0.53 ± 0.07 0.85 
Data as means ± standard error of the mean from Experiment 1. 
*One radiograph was lost. 
Table 5. Norberg angles, radiographic scores and pathologic scores of hip joints at eight 
months of age in control and treated dogs for Experiment 2. 
Untreated Controls Drug Treated 
Norberg Norberg 
Dog Angle Radiographic Pathologic Dog Angle Radiographic Pathologic 
No. Average* Diag.* Score* Score* No. Average* Diag.* Score* Score* 
F59 110° N 1 0 F19 111° N 1 0 
F69 99o D 5 5.5 F29 113° N 1 0.5 
F79 104° N 2 0 F39 111° N 2 1.0 
F89 104° N 1 0 F49 110° N 2 0 
G59 108° N 2 0.5 Gl9 108° N 2 1 
G69 96° D (R2) t 3 5.5 G29 110° N 3 2 
(L4) 
G79 101° D (R4) 3 6.5 G39 104° N 3 6.5 
(L2) 
G89 91° D 6 8 G49 110° N 2 1.5 
*Degree, diagnosis and score numbers are "per dog." 
tR = right joint; L = left joint. 
w 
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Table 6. Effects of intramuscular injections of 5.0 ug/Kg 
glycosaminoglycan polysulfates on hip joint radiographic and 
intra-articular parameters at eight months of age. 
Untreated Drug Probability 
Controls Treated p 
Radiographic Diagnosis 4 N; 4 D 8 N; 0 D 0.04 
Radiographic Score 2.9 ± 0.5 2.0 ± 0.3 0.10 
Norberg Angle (degrees) 101.5 ± 1.6 109.7 ± 1.6 0.002 
Center-edge Angle (degrees) 12.9 ± 1.5 19.3 ± 1.5 0.006 
Femoral head coverage (%) 38.7 ± 2.3 41.9 ± 2.3 0.17 
Distraction (mm) 7.9 ± 0.6 7.1 ± 0.6 0.20 
Distraction index 0.65 ± 0.05 0.59 ± 0.05 0.23 
Pathologic Score 3.3 ± 0.9 1.6 ± 0.9 0.09 
Synovial fluid vol. (ml) 0.39 ± .12 0.23 ± .12 0.17 
Ligament vol. (ml) 0.76 ± .06 0.68 ± .06 0.18 
Cartilage 
Proteoglycan (ug/mg) 36.4 ± 2.9 3 6. 4 ± 2.4 
Fibronectin (ug/mg) 2.19 ± 0.61 0.59 ± .56 0.04 
Data from Experiment 2; expressed as means and standard error of 
mean. 
Table 7. Comparison of overall experimental measurements with those calculated for normal and 
dysplastic hip joints of the Labrador retrievers used in Experiment 2. 
Normal Joints Dysplastic Joints Untreated* Drug* 
Parameter Units Expected Observed* Expected Observed** Controls Treated 
Radiograph - N N D D N-D N 
Norberg angle degrees >102 109.4±1.0 <101 96.9±1.7 101.5±1.7 109.7.±0.9 
Center-edge degrees > 12 19.2±0.7 < 11 8. 3±1. 7 12.9±1.7 19.3±0.7 
Joint laxity mm 1-4 6.9±0.7 > 4 10.3± .7 7.8±0.7 7.1±0.5 
Distraction index - <0.3 0.5±.02 >.3 0.83±.03 0.7±.05 0.6±0.4 
Femoral coverage % > 40 44.7±1.0 <39 32.5±2.8 38.7±2.3 41.9±1.5 
Synovial fluid ml < 0.3 0.2±.03 >0.4 0.7±0.1 0.4±.1 0.23±.04 
Ligament volume ml < 0.7 0.60±.06 >0.7 1. 0±0 .1 0.78±.06 0.68±.06 
Cartilage - smooth smooth rough rough variable variable 
Fibronectin ug/mg < 0.4 0.32±.03 >0.5 3.52±0.7 2.30±.66 0.62±0.2 
Proteoglycan ug/mg 3.0-45 38.2±1.7 5-29 28.6±2.8 36.4±2.9 36.4±2.4 
"Expected" values represent literature values taken from references 10, 11, 12, 14, 16, 17, 
18, and 19. 
*Mean and SEM from joints of dogs with normal radiograph and disease-free cartilage 
at necropsy. 
**Mean and SEM from joints of dogs with a diagnosis of dysplastic and with cartilage 
degeneration. 
*Experimental data from Table 6; mean values from untreated controls and from treated dogs. 
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Table 8. Lack of effect of glycosaminoglycan polysulfates treat-
ment in growing dogs on cartilage proteoglycan and fibronectin 
content of normal shoulder joints. 
Untreated Drug 
Controls Treated 
Proteoglycan (ug/mg) 36.4 ± 2.9 36.4 ± 2.4 
Fibronectin (ug/mg) 0.21 ± .03 0.31 ± .07 
Synovial fluid (ml) 0.41 ± .06 0.48 ± .04 
Data from Experiment 2; expressed as means and standard error of 
mean. 
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Figure 1. Growth of pups in experiments 1 and 2. 
